Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > POC

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 21, 2022 3:34pm

91 Views

Post# 34841388

RE:RE:RE:RE:RE:RE:RE:RE:RE:POC

"I am now convinced that POC is whatever any of us wants to think it is!"

That might be the best take on this yet.

SPCEO1 wrote: I still don't speak much with the company these days, typcially once a quarter and those opportunities are brief and focused on Christian/science. But good memory to pull that out of the past! I am now convinced that POC is whatever any of us wants to think it is!

palinc2000 wrote: The following is an extract from the Press Release announcing the acquisition of Katana

Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. Katana shareholders will have the right to receive two milestone payments. The first milestone payment will occur when the first patient for the proof of concept 2 trial is enrolled. At that time, approximately US$1,500,000 will be paid through the issuance of common shares of Theratechnologies. The second milestone will be met when the proof of concept is demonstrated in human subjects, which should be by the end of 2021. This payment will amount to US$1,800,000 in common shares of Theratechnologies.

I dont recall that the second milestone payment upon demonstration of POC has been made ....However I have some recollection that this was amended in a later agreement....Perhaps the Company did realize that POC was too an ill defined terms ,,,,I think if SPCEO could find out in a less than 1 minute phone call with the CFO ...that would at least clarify the discussion